Guardant Health (GH) Misses Q4 EPS by 37c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Piper Sandler Starts SoFi Technologies (SOFI) at Overweight
- Fulcrum Therapeutics to merge with Slate Medicines in all-stock deal
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
Guardant Health Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Revenue Outlook for Full Year 2021
February 24, 2021 4:05 PM EST2020 Revenue Increased 34% Over Prior Year Period
REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today reported financial results for the quarter and full year ended December 31, 2020.
Recent Highlights
Revenue of $78.3 million for the fourth quarter and $286.7 million for the full year of 2020, representing 25% and 34% increases, respectively, over the corresponding periods of 2019 Launched... More